@FierceMedDev: ICYMI: ReWalk squeaks by with $36M IPO as oncology device player Mevion files to raise up to $69M. Article | Follow @FierceMedDev
@MichaelGFierce: HIV-fighting intravaginal ring research nets $20M from NIH. FierceDrugDelivery story | Follow @MichaelGFierce
> A study to be published in Fertility & Sterility found that the EmbryoScope time-lapse system significantly benefited reproduction rates. Release
> Biomet CEO, Jeffrey Binder met with "company A's" CEO in December 2013 to discuss a potential merger, before deciding to accept Zimmer's offer in 2014. Story
> Genomic Health's Oncotype DX colon cancer test may result in a significant reduction in direct medical costs, according to an economic analysis published in PharmacoEconomics. Release
> The smartphone sensor-powered Phone Oximeter pulse oximeter is a low-cost Sepsis monitoring system aiming to reduce deaths in the developing world for patients with sepsis, children with pneumonia, and women with preeclampsia. Release
Biotech News
@FierceBiotech: Arch, Polaris back a $20M round for Scholar Rock's immune system R&D platform. Article | Follow @FierceBiotech
@JohnCFierce: This $AVNR "drug" is what gives biotech a bad name--simply awful. | Follow @JohnCFierce
@DamianFierce: ICYMI: $BIIB and $ABBV plan to market the monthly MS shot daclizumab as Zinbryta, filing in 2015. Release | Follow @DamianFierce
@EmilyMFierce: Well, this is an interesting development. Nature reviewers not persuaded by initial STAP stem cell papers. More from Science | Follow @EmilyMFierce
> Avanir skyrockets as its controversial generic combo claims a hit in PhII Alzheimer's study. Report
> Cancer R&D stars pitch an $86M biotech IPO for Kolltan Pharma. Story
> Roche's Genentech triggers its PhIII program for blockbuster AMD contender. News
Pharma News
@FiercePharma: Tops in FP this weekend: Analysts: Pfizer execs say they're locked-and-loaded on tax inversion, and open to targets. Article | Follow @FiercePharma
@EricPFierce: Apotex, which has had plenty of cGMP issues of its own, is recalling generic Paxil made at GSK plant. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce
@CarlyHFierce: ICYMI: This week's issue of FierceVaccines. To get it every week, subscribe here. | Follow @CarlyHFierce
> Balky payers, beware: Gilead eyes $95K-or-so price for Sovaldi combo pill. Article
> Salix hands off Relistor, other drugs to Lupin in Canada. News
> Mylan, Ranbaxy, others to bring cheap Sovaldi to 91 markets. Story
CRO News
> Evotec signs a Huntington's deal as diabetes project falls through. Report
> Quintiles homes in on small biotechs with new service offering. More
> Recruitment specialist Trialbee snags a deal with AstraZeneca. Item
> Icon and Medidata unite to give patients a louder voice in clinical trials. Article
> PRA swings for $375M in the next big CRO IPO. News
Biotech IT News
> Wearables project aims to provide new source of data for MS trials. Story
> Application of regulatory handbrake to 23andMe offers cautionary tale to Silicon Valley. Report
> NCI turns to Dell for pediatric cancer research project. More
> AstraZeneca taps Trialbee for online patient recruitment. Article
> Mayo Clinic to apply IBM's Watson to matching patients to trials. Story
Animal Health News
> FDA seeks input on conditional approvals for new animal health products. Report
> Merck launches new vaccine to fight PRRS in pig herds. More
> European Commission adds new proposals for use of veterinary meds and medicated feed. Story
> Alivira snaps up 60% stake in Turkey's Provet Veterinary Products. Article
> Dechra Pharmaceuticals reports gains in full-year profit. Report